- Home
- ALXO vs CSBR Comparison
ALXO vs CSBR Comparison
Compare ALXO & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- CSBR
- Stock Information
- Founded
- ALXO 2015
- CSBR 1985
- Country
- ALXO United States
- CSBR United States
- Employees
- ALXO N/A
- CSBR N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALXO Health Care
- CSBR Health Care
- Exchange
- ALXO Nasdaq
- CSBR Nasdaq
- Market Cap
- ALXO 81.1M
- CSBR 65.9M
- IPO Year
- ALXO 2020
- CSBR 1986
- Fundamental
- Price
- ALXO $1.41
- CSBR $4.55
- Analyst Decision
- ALXO Strong Buy
- CSBR Strong Buy
- Analyst Count
- ALXO 6
- CSBR 1
- Target Price
- ALXO $14.20
- CSBR $6.00
- AVG Volume (30 Days)
- ALXO 886.3K
- CSBR 11.0K
- Earning Date
- ALXO 11-07-2024
- CSBR 12-10-2024
- Dividend Yield
- ALXO N/A
- CSBR N/A
- EPS Growth
- ALXO N/A
- CSBR N/A
- EPS
- ALXO N/A
- CSBR N/A
- Revenue
- ALXO N/A
- CSBR $51,655,000.00
- Revenue This Year
- ALXO N/A
- CSBR $9.27
- Revenue Next Year
- ALXO N/A
- CSBR $9.76
- P/E Ratio
- ALXO N/A
- CSBR N/A
- Revenue Growth
- ALXO N/A
- CSBR N/A
- 52 Week Low
- ALXO $1.19
- CSBR $3.60
- 52 Week High
- ALXO $17.83
- CSBR $7.13
- Technical
- Relative Strength Index (RSI)
- ALXO 47.30
- CSBR 54.89
- Support Level
- ALXO $1.19
- CSBR $4.26
- Resistance Level
- ALXO $1.63
- CSBR $4.67
- Average True Range (ATR)
- ALXO 0.11
- CSBR 0.27
- MACD
- ALXO 0.01
- CSBR 0.02
- Stochastic Oscillator
- ALXO 50.00
- CSBR 76.19
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.